LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer
Authors:
- Fanny DupuyFDFanny Dupuy
- Takla GrissTGTakla Griss
- Julianna BlagihJBJulianna Blagih
- Gäelle BridonGBGäelle Bridon
- Daina AvizonisDADaina Avizonis
- Chen LingCLChen Ling
- Zhifeng DongZDZhifeng Dong
- Doris R SiwakDSDoris R Siwak
- Matthew G AnnisMAMatthew G Annis
- Gordon B MillsGMGordon B Mills
- William J MullerWMWilliam J Muller
- Peter M SiegelPSPeter M Siegel
Open Access
- 14 August 2013
- journal article
- Published by Springer Nature in Cancer & Metabolism
- Vol. 1 (1) , 18
Abstract
Background: Germline and somatic mutations in STK11, the gene encoding the serine/threonine kinase LKB1, are strongly associated with tumorigenesis. While loss of LKB1 expression has been linked to breast cancer, the mechanistic role of LKB1 in regulating breast cancer development, metastasis, and tumor metabolism has remained unclear. Methods: We have generated and analyzed transgenic mice expressing ErbB2 in the mammary epithelium of LKB1 wild-type or LKB1-deficient mice. We have also utilized ErbB2-expressing breast cancer cells in which LKB1 levels have been reduced using shRNA approaches. These transgenic and xenograft models were characterized for the effects of LKB1 loss on tumor initiation, growth, metastasis and tumor cell metabolism. Results: We demonstrate that loss of LKB1 promotes tumor initiation and induces a characteristic shift to aerobic glycolysis (‘Warburg effect’) in a model of ErbB2-mediated breast cancer. LKB1-deficient breast cancer cells display enhanced early tumor growth coupled with increased cell migratory and invasive properties in vitro. We show that ErbB2-positive tumors deficient for LKB1 display a pro-growth molecular and phenotypic signature characterized by elevated Akt/mTOR signaling, increased glycolytic metabolism, as well as increased bioenergetic markers both in vitro and in vivo. We also demonstrate that mTOR contributes to the metabolic reprogramming of LKB1-deficient breast cancer, and is required to drive glycolytic metabolism in these tumors; however, LKB1-deficient breast cancer cells display reduced metabolic flexibility and increased apoptosis in response to metabolic perturbations. Conclusions: Together, our data suggest that LKB1 functions as a tumor suppressor in breast cancer. Loss of LKB1 collaborates with activated ErbB2 signaling to drive breast tumorigenesis and pro-growth metabolism in the resulting tumors.Keywords
This publication has 50 references indexed in Scilit:
- LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug PhenforminCancer Cell, 2013
- AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In VivoCell Metabolism, 2013
- CCN3 Impairs Osteoblast and Stimulates Osteoclast Differentiation to Favor Breast Cancer Metastasis to BoneThe American Journal of Pathology, 2011
- Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung TumorsCancer Cell, 2010
- Glucose Addiction of TSC Null Cells Is Caused by Failed mTORC1-Dependent Balancing of Metabolic Demand with SupplyMolecular Cell, 2010
- The LKB1–AMPK pathway: metabolism and growth control in tumour suppressionNature Reviews Cancer, 2009
- LKB1 is required for adiponectin-mediated modulation of AMPK–S6K axis and inhibition of migration and invasion of breast cancer cellsOncogene, 2009
- AMPK Phosphorylation of Raptor Mediates a Metabolic CheckpointMolecular Cell, 2008
- ShcA signalling is essential for tumour progression in mouse models of human breast cancerThe EMBO Journal, 2008
- LKB1 modulates lung cancer differentiation and metastasisNature, 2007